93 related articles for article (PubMed ID: 12001649)
1. Role of inflammatory factors in neurodegeneration.
Członkowska A; Kurkowska-Jastrzebska I; Członkowski A
Neurol Neurochir Pol; 2001; 35 Suppl 3():13-22. PubMed ID: 12001649
[No Abstract] [Full Text] [Related]
2. [Treatment of neurodegenerative diseases: new perspectives].
Członkowska A; Kurkowska-Jastrzebska I
Neurol Neurochir Pol; 2001; 35(4 Suppl):147-56. PubMed ID: 11873614
[TBL] [Abstract][Full Text] [Related]
3. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.
De Lella Ezcurra AL; Chertoff M; Ferrari C; Graciarena M; Pitossi F
Neurobiol Dis; 2010 Mar; 37(3):630-40. PubMed ID: 19969084
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and neurodegeneration in Parkinson's disease.
McGeer PL; McGeer EG
Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S3-7. PubMed ID: 15109580
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic Parkinson's disease: a review of clinical types and pathology.
Olasode BJ
Niger J Med; 2001; 10(3):116-20. PubMed ID: 11806009
[TBL] [Abstract][Full Text] [Related]
6. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
7. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.
Miklossy J; Doudet DD; Schwab C; Yu S; McGeer EG; McGeer PL
Exp Neurol; 2006 Feb; 197(2):275-83. PubMed ID: 16336966
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of cell death in experimental models of Parkinson's disease.
Hirsch EC; Hunot S; Hartmann A
Funct Neurol; 2000; 15(4):229-37. PubMed ID: 11213526
[No Abstract] [Full Text] [Related]
9. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.
Liberatore GT; Jackson-Lewis V; Vukosavic S; Mandir AS; Vila M; McAuliffe WG; Dawson VL; Dawson TM; Przedborski S
Nat Med; 1999 Dec; 5(12):1403-9. PubMed ID: 10581083
[TBL] [Abstract][Full Text] [Related]
10. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.
Korecka JA; Eggers R; Swaab DF; Bossers K; Verhaagen J
Restor Neurol Neurosci; 2013; 31(2):155-67. PubMed ID: 23271419
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice.
Chertoff M; Di Paolo N; Schoeneberg A; Depino A; Ferrari C; Wurst W; Pfizenmaier K; Eisel U; Pitossi F
Exp Neurol; 2011 Feb; 227(2):237-51. PubMed ID: 21093436
[TBL] [Abstract][Full Text] [Related]
12. Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease.
Bayersdorfer F; Voigt A; Schneuwly S; Botella JA
Neurobiol Dis; 2010 Oct; 40(1):113-9. PubMed ID: 20211259
[TBL] [Abstract][Full Text] [Related]
13. The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.
Yantiri F; Andersen JK
IUBMB Life; 1999 Aug; 48(2):139-41. PubMed ID: 10794588
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
Delgado M; Ganea D
FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
[TBL] [Abstract][Full Text] [Related]
15. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease.
Kazantsev AG; Kolchinsky AM
Arch Neurol; 2008 Dec; 65(12):1577-81. PubMed ID: 19064744
[TBL] [Abstract][Full Text] [Related]
16. [Biological psychiatry. 1) The dopamine-acetylcholine equilibrium model].
Adèr JP
TVZ; 1988 Jan; 42(1):13-6. PubMed ID: 2895504
[No Abstract] [Full Text] [Related]
17. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
[TBL] [Abstract][Full Text] [Related]
18. S-allylcysteine reduces the MPTP-induced striatal cell damage via inhibition of pro-inflammatory cytokine tumor necrosis factor-α and inducible nitric oxide synthase expressions in mice.
García E; Villeda-Hernández J; Pedraza-Chaverrí J; Maldonado PD; Santamaría A
Phytomedicine; 2010 Dec; 18(1):65-73. PubMed ID: 20576415
[TBL] [Abstract][Full Text] [Related]
19. Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP.
Samantaray S; Knaryan VH; Butler JT; Ray SK; Banik NL
J Neurochem; 2008 Mar; 104(5):1309-20. PubMed ID: 18036149
[TBL] [Abstract][Full Text] [Related]
20. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
